Pleiotropic effects of atorvastatin in peritoneal dialysis patients: A retrospective-prospective observational cohort study

Abstract. Recent studies demonstrate a large number of non-lipid modifiable effects statins in various diseases. However, although atherogenic dyslipidemia is common feature peritoneal dialysis (PD) patients, use supported by limited data and there general lack research on their pleiotropic this patients’ cohort. The present study aimed to evaluate the possible atorvastatin PD patients.
 Methods. A total 114 patients with an average age 55 (48-65) years vintage 31 (14-50) months were included combined retrospective prospective multicentre cohort study. (n = 54) who had started receiving before or after initiation been treated no less than 12 Atorvastatin Group. 60) have never taken consisted Atorvastatin-free Group.
 In addition routine clinical adequacy tests, concentrations interleukins -6, -10, tumor necrosis factor-alpha, monocyte chemoattractant protein-1 effluent (PDE) evaluated all participants at start follow-up period. primary outcomes 3-year technique survival all-cause mortality during period.
 Results. users lower serum phosphate parathyroid hormone concentrations, higher weekly creatinine clearance, Kt/V urea, and, accordingly, compared PDE cytokines assessment demonstrated significantly studied Group Cox regression models, was associated better (HR 0.28 (95% CI 0.15; 0.54), p 0.003) reduction regardless age, diabetes, anuric status, albumin C-reactive protein levels, history peritonitis 0.24 0.44), < 0.0001).
 Conclusions. treatment normalization phosphate-calcium metabolism, low intraperitoneal inflammation incidence PD-associated peritonitis, our patients. These may be one reasons for all‐cause Further are needed determine necessity prescribing